首页> 外文期刊>International journal of oncology >Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells
【24h】

Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells

机译:I类组蛋白脱乙酰基酶抑制剂通过增强侵袭性人TNBC细胞中肿瘤抑制因子和抗血管生成基因的表达来抑制血管生成拟态

获取原文
       

摘要

Triple-negative breast cancer (TNBC) cells form angiogenesis-independent vessel-like structures to survive, known as vasculogenic mimicry (VM), contributing to a poor prognosis for cancer patients. Nuclear localized class I histone deacetylases (HDACs) enzymes, particularly HDACs 1, 2, 3 deacetylate chromatin histones, are overexpressed in cancers and epigenetically regulate the expression of genes involved in cancer initiation and progression. The specific HDAC inhibitor, entinostat, has been shown to attenuate tumor progression and metastasis in TNBC. In this study, we hypothesized that entinostat would enhance the expression of anti-angiogenic and tumor suppressor genes and would thus suppress VM structures in TNBC cells in a 3D Matrigel cell culture preclinical model. Our data indicated that invasive triple-negative MDA-MB-231, LM2-4 and BT-549 breast cancer cells, but not poorly invasive luminal MCF-7 cells, efficiently underwent matrix-associated VM formation. Approximately 80% of TNBC cells with the stem cell phenotype potential formed vessel-like structures when mixed with Matrigel and cultured in the low attachment tissue culture plate. The molecular mechanisms of VM formation are rather complex, while angiogenesis inhibitor genes are downregulated and pro-angiogenesis genes are upregulated in VM-forming cells. Our data revealed that treatment of the TNBC VM phenotype cells with entinostat epigenetically led to the re-expression of the anti-angiogenic genes, serpin family F member 1 (SERPINF1) and thrombospondin 2 (THBS2), and to that of the tumor suppressor genes, phosphatase and tensin homolog (PTEN) and p21, and reduced VM structures. We also found that treatment of the TNBC VM phenotype cells with entinostat downregulated the expression of vascular endothelial growth factor A (VEGF-A), and that of the epithelial-mesenchymal transition (EMT)-related genes, Vimentin and β-catenin. METABIRC and TCGA breast cancer cohort mRNA expression data analysis revealed that a high expression of the anti-angiogenesis-associated genes, THBS2, SERPINF1 and serpin family B member 5 (SERPINB5), and of the tumor suppressor gene, PTEN, was associated with a better overall survival (OS) of breast cancer patients. Taken together, the findings of this study demonstrate that HDACs 1, 2, 3 partly contribute to VM formation in TNBC cells; thus, HDACs may be an important therapeutic target for TNBC.
机译:三阴性乳腺癌(TNBC)细胞形成独立于血管生成的血管样结构,以维持生存,这被称为血管生成模拟(VM),导致癌症患者的预后较差。核定位的I类组蛋白脱乙酰基酶(HDAC)酶,特别是HDAC 1、2、3脱乙酰基染色质组蛋白,在癌症中过表达,并在表观遗传学上调控与癌症发生和发展有关的基因的表达。特定的HDAC抑制剂恩替司他已显示可减轻TNBC中的肿瘤进展和转移。在这项研究中,我们假设恩替司他将增强抗血管生成和肿瘤抑制基因的表达,从而在3D Matrigel细胞培养的临床前模型中抑制TNBC细胞中的VM结构。我们的数据表明,侵袭性三阴性MDA-MB-231,LM2-4和BT-549乳腺癌细胞有效地经历了基质相关的VM形成,但侵袭性差的管腔MCF-7细胞却没有。与Matrigel混合并在低附着组织培养板中培养时,具有干细胞表型潜力的TNBC细胞中约80%形成了血管样结构。 VM形成的分子机制相当复杂,而在VM形成细胞中血管生成抑制剂基因被下调,而促血管生成基因则被上调。我们的数据显示,用恩替司他表观治疗TNBC VM表型细胞可导致抗血管生成基因,丝氨酸蛋白酶抑制剂家族F成员1(SERPINF1)和血小板反应蛋白2(THBS2)以及肿瘤抑制基因的重新表达。 ,磷酸酶和张力蛋白同源物(PTEN)和p21,以及降低的VM结构。我们还发现用恩替司他处理TNBC VM表型细胞可下调血管内皮生长因子A(VEGF-A)的表达以及上皮-间质转化(EMT)相关基因Vimentin和β-catenin的表达。 METABIRC和TCGA乳腺癌队列的mRNA表达数据分析表明,抗血管生成相关基因THBS2,SERPINF1和serpin B家族5成员(SERPINB5)的高表达与抑癌基因PTEN的高表达有关。乳腺癌患者的总体生存率更高。两者合计,这项研究的结果表明HDACs 1,2,3部分有助于TNBC细胞中VM的形成。因此,HDACs可能是TNBC的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号